Prostate Carcinoma Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Verified date | April 2024 |
Source | Alliance for Clinical Trials in Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
Status | Active, not recruiting |
Enrollment | 88 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men who are currently receiving androgen deprivation therapy (ADT) for the treatment of prostate cancer. ADT is defined by a history of orchiectomy, or ongoing usage of gonadotropin-releasing hormone agonists or antagonists. Men receiving abiraterone, but not enzalutamide, apalutamide, and darolutamide are eligible, as the latter three are metabolized by CYP3A4 and may affect oxybutynin serum concentrations. - Patients must be on a stable dose of all hormone-directed therapies for at least 28 days prior to registration and must not be planning to discontinue this therapy for at least 42 days following registration. Patients receiving radiation therapy during the study period are eligible - Eligible patient must have bothersome hot flashes for >= 14 days prior to registration, defined by an occurrence of >= 28 times per week and of sufficient severity to cause the patient to seek therapeutic intervention - Life expectancy of greater than 6 months - Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, or 2 - In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English Exclusion Criteria: - No current use or future planned use of any of the following agents during the study period: drugs that are not Food and Drug Administration (FDA) approved for use in humans, androgens, estrogens, progesterone analogs, gabapentin, selective serotonin reuptake inhibitor (SSRI)/serotonin and norepinephrine reuptake inhibitor (SNRI) anti-depressants, cholinergic agonists, cholinesterase inhibitors, or complementary/alternative medicine taken for the purpose of managing hot flashes. Prior use of these agents is permitted as long as they are discontinued before registration - No current or prior use of oxybutynin - Patients with a history of any of the following contraindications to oxybutynin are not eligible: gastroparesis or gastrointestinal obstructive disorders; significant gastric reflux symptoms not controlled by medication; ulcerative colitis; narrow-angle glaucoma; urinary retention requiring indwelling or intermittent self-catheterization within the prior 6 months; hypersensitivity to oxybutynin or any other components of the product; current uncontrolled hyperthyroidism; uncontrolled coronary artery disease or a history of myocardial infarction within the prior 12 months; New York Heart Association (NYHA) class II-IV congestive heart failure; symptomatic cardiac arrhythmias; current uncontrolled hypertension; myasthenia gravis; or dementia |
Country | Name | City | State |
---|---|---|---|
United States | Hawaii Cancer Care - Westridge | 'Aiea | Hawaii |
United States | Mary Greeley Medical Center | Ames | Iowa |
United States | McFarland Clinic - Ames | Ames | Iowa |
United States | Langlade Hospital and Cancer Center | Antigo | Wisconsin |
United States | Ascension Saint Elizabeth Hospital | Appleton | Wisconsin |
United States | Messino Cancer Centers | Asheville | North Carolina |
United States | McFarland Clinic - Boone | Boone | Iowa |
United States | Montefiore Medical Center - Moses Campus | Bronx | New York |
United States | Montefiore Medical Center-Einstein Campus | Bronx | New York |
United States | Montefiore Medical Center-Weiler Hospital | Bronx | New York |
United States | Ascension Southeast Wisconsin Hospital - Elmbrook Campus | Brookfield | Wisconsin |
United States | Fairview Ridges Hospital | Burnsville | Minnesota |
United States | Minnesota Oncology - Burnsville | Burnsville | Minnesota |
United States | AtlantiCare Health Park-Cape May Court House | Cape May Court House | New Jersey |
United States | Ascension Calumet Hospital | Chilton | Wisconsin |
United States | Southeastern Medical Oncology Center-Clinton | Clinton | North Carolina |
United States | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia | Missouri |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Mercy Hospital | Coon Rapids | Minnesota |
United States | Carle at The Riverfront | Danville | Illinois |
United States | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Iowa Methodist Medical Center | Des Moines | Iowa |
United States | Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa |
United States | Mercy Medical Center - Des Moines | Des Moines | Iowa |
United States | Fairview Southdale Hospital | Edina | Minnesota |
United States | Carle Physician Group-Effingham | Effingham | Illinois |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | AtlantiCare Surgery Center | Egg Harbor Township | New Jersey |
United States | Sanford Broadway Medical Center | Fargo | North Dakota |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Genesee Cancer and Blood Disease Treatment Center | Flint | Michigan |
United States | Genesee Hematology Oncology PC | Flint | Michigan |
United States | Genesys Hurley Cancer Institute | Flint | Michigan |
United States | McFarland Clinic - Trinity Cancer Center | Fort Dodge | Iowa |
United States | Ascension Saint Francis - Reiman Cancer Center | Franklin | Wisconsin |
United States | Unity Hospital | Fridley | Minnesota |
United States | Arizona Breast Cancer Specialists-Gilbert | Gilbert | Arizona |
United States | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina |
United States | Altru Cancer Center | Grand Forks | North Dakota |
United States | Grand Valley Oncology | Grand Junction | Colorado |
United States | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu | Hawaii |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Baptist MD Anderson Cancer Center | Jacksonville | Florida |
United States | Southeastern Medical Oncology Center-Jacksonville | Jacksonville | North Carolina |
United States | McFarland Clinic - Jefferson | Jefferson | Iowa |
United States | Fairview Clinics and Surgery Center Maple Grove | Maple Grove | Minnesota |
United States | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota |
United States | Saint John's Hospital - Healtheast | Maplewood | Minnesota |
United States | McFarland Clinic - Marshalltown | Marshalltown | Iowa |
United States | Sovah Health Martinsville | Martinsville | Virginia |
United States | Fremont - Rideout Cancer Center | Marysville | California |
United States | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois |
United States | Ascension Columbia Saint Mary's Hospital Ozaukee | Mequon | Wisconsin |
United States | Ascension Columbia Saint Mary's Hospital - Milwaukee | Milwaukee | Wisconsin |
United States | Ascension Southeast Wisconsin Hospital - Saint Joseph Campus | Milwaukee | Wisconsin |
United States | Zablocki Veterans Administration Medical Center | Milwaukee | Wisconsin |
United States | Abbott-Northwestern Hospital | Minneapolis | Minnesota |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | Monticello Cancer Center | Monticello | Minnesota |
United States | ProHealth D N Greenwald Center | Mukwonago | Wisconsin |
United States | Cancer Center of Western Wisconsin | New Richmond | Wisconsin |
United States | New Ulm Medical Center | New Ulm | Minnesota |
United States | NYP/Weill Cornell Medical Center | New York | New York |
United States | Cancer Care Center of O'Fallon | O'Fallon | Illinois |
United States | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin |
United States | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha | Nebraska |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | Ascension Mercy Hospital | Oshkosh | Wisconsin |
United States | Arizona Center for Cancer Care-Peoria | Peoria | Arizona |
United States | Arizona Breast Cancer Specialists-Phoenix | Phoenix | Arizona |
United States | Cancer Center at Saint Joseph's | Phoenix | Arizona |
United States | Ascension All Saints Hospital | Racine | Wisconsin |
United States | North Memorial Medical Health Center | Robbinsdale | Minnesota |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Delbert Day Cancer Institute at PCRMC | Rolla | Missouri |
United States | Ascension Saint Mary's Hospital | Saginaw | Michigan |
United States | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan |
United States | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | United Hospital | Saint Paul | Minnesota |
United States | Arizona Breast Cancer Specialists | Scottsdale | Arizona |
United States | Arizona Breast Cancer Specialists-Scottsdale | Scottsdale | Arizona |
United States | Saint Francis Regional Medical Center | Shakopee | Minnesota |
United States | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Southern Illinois University School of Medicine | Springfield | Illinois |
United States | Springfield Clinic | Springfield | Illinois |
United States | Lakeview Hospital | Stillwater | Minnesota |
United States | Arizona Center for Cancer Care-Surprise | Surprise | Arizona |
United States | Ascension Saint Joseph Hospital | Tawas City | Michigan |
United States | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California |
United States | University of Arizona Cancer Center-North Campus | Tucson | Arizona |
United States | Carle Cancer Center | Urbana | Illinois |
United States | Ridgeview Medical Center | Waconia | Minnesota |
United States | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin |
United States | Aspirus Regional Cancer Center | Wausau | Wisconsin |
United States | Ascension Medical Group Southeast Wisconsin - Mayfair Road | Wauwatosa | Wisconsin |
United States | Rice Memorial Hospital | Willmar | Minnesota |
United States | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids | Wisconsin |
United States | Minnesota Oncology Hematology PA-Woodbury | Woodbury | Minnesota |
United States | Fairview Lakes Medical Center | Wyoming | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Alliance for Clinical Trials in Oncology | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient-reported hot flash scores | Using patients' hot flash diaries, daily hot flash scores will be determined by multiplying the frequency of each defined hot flash grade by the severity and summing the values over a 24-hour period. Weekly hot flash scores will be computed by averaging these hot flash scores across 7 days. A mixed model will be estimated that includes baseline and weekly hot flash scores across the 6-week treatment period. Estimates from the mixed model will be used to construct 90% confidence intervals for mean differences in hot flash score reduction from baseline to 6 weeks between the oxybutynin and placebo arms. Contrasts estimated via the mixed model will involve a two-sided t-test with alpha = .10. At 6 weeks, the proportion of patients who experience a 50% or greater reduction in hot flash scores since baseline will be compared across the oxybutynin and placebo arms using Fisher's exact test or logistic regression. | Baseline up to 6 weeks post-randomization | |
Secondary | Patient-reported hot flash frequency | Weekly hot flash frequencies will be determined by patients' hot flash diaries. A mixed model will be estimated that includes baseline and weekly hot flash frequencies across the 6-week treatment period. The mixed model and subsequent contrasts will account for the observed distribution of weekly hot flash frequencies. At 6 weeks, the proportion of patients who experience a 50% or greater reduction in hot flash frequency since baseline will be compared across the oxybutynin and placebo arms using Fisher's exact test or logistic regression. Consistency of the results will be assessed across the various methods used to evaluate the efficacy of oxybutynin in this trial (i.e., hot flash scores versus hot flash frequencies, mean differences versus 50% or greater reduction since baseline, single day versus full week to define patients' baseline hot flash scores). | Baseline up to 6 weeks post-randomization | |
Secondary | Incidence of adverse events | Grade 3 or higher adverse events will be assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 and summarized by arm. | Baseline up to 12 weeks post-randomization | |
Secondary | Patient-reported symptoms | Patient-reported symptoms will be assessed by the Symptom Experience Questionnaire. A mixed model will be estimated that includes baseline and weekly patient-reported symptoms across the 6-week treatment period. Estimates from the mixed model will be used to construct 90% confidence intervals for mean differences in patient-reported symptoms between the oxybutynin and placebo arms at 6 weeks. Contrasts estimated via the mixed model will involve a two-sided t-test with alpha = .10. | Baseline and at the end of each week of treatment, assessed up to 6 weeks post-randomization | |
Secondary | Patient accrual | The time required to accrue 87 patients will be reported. | Up to 2 years | |
Secondary | Treatment adherence rates | Treatment adherence rates will be calculated by dividing the number of patients who completed treatment per protocol by the number of patients who started treatment. Treatment adherence rates will be summarized by arm. | Up to 2 years | |
Secondary | Patient-reported quality of life: scale | A mixed model will be estimated that includes patients' scores on the Hot Flash Related Daily Interference Scale (HFRDIS) across the 6-week treatment period. Estimates from the mixed model will be used to construct 90% confidence intervals for mean differences in patient-reported quality of life between the oxybutynin and placebo arms at 6 weeks. Contrasts estimated via the mixed model will involve a two-sided t-test with alpha = .10. | Baseline and at the end of each week of treatment, assessed up to 6 weeks post-randomization | |
Secondary | Patient-reported hot flash interference | A mixed model will be estimated that includes patients' scores on the Hot Flash Related Daily Interference Scale (HFRDIS) across the 6-week treatment period. Estimates from the mixed model will be used to construct 90% confidence intervals for mean differences in patient-reported hot flash interference between the oxybutynin and placebo arms at 6 weeks. Contrasts estimated via the mixed model will involve a two-sided t-test with alpha = .10. | Baseline and at the end of each week of treatment, assessed up to 6 weeks post-randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04457232 -
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
|
Phase 1 | |
Active, not recruiting |
NCT03661437 -
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
|
Early Phase 1 | |
Completed |
NCT02337465 -
KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
|
N/A | |
Completed |
NCT03013413 -
Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy
|
N/A | |
Recruiting |
NCT06037863 -
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
|
N/A | |
Active, not recruiting |
NCT03580499 -
Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
|
N/A | |
Completed |
NCT03326440 -
Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer
|
N/A | |
Recruiting |
NCT04597359 -
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
|
Phase 2 | |
Active, not recruiting |
NCT03263650 -
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
|
Phase 2 | |
Active, not recruiting |
NCT04299620 -
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
|
N/A | |
Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
Completed |
NCT02957981 -
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
|
N/A | |
Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
Enrolling by invitation |
NCT06347809 -
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
|
||
Enrolling by invitation |
NCT04254133 -
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
|
||
Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT00002540 -
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Completed |
NCT03101046 -
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
|
Phase 2 |